Telatinib
|
- ₹0
- Product name: Telatinib
- CAS: 332012-40-5
- MF: C20H16ClN5O3
- MW: 409.83
- EINECS:
- MDL Number:MFCD18251453
- Synonyms:2-Pyridinecarboxamide, 4-(((4-((4-chlorophenyl)amino)furo(2,3-D)pyridazin-7-yl)oxy)methyl)-N-methyl-;Bay 57-9352;Unii-18p7197Q7j;Telatinib(BAY 57-9352);4-[[[4-[(4-Chlorophenyl)amino]furo[2,3-d]pyridazin-7-yl]oxy]methyl]-N-methyl-2-pyridinecarboxamide;4-((4-(4-chlorophenylamino)furo[2,3-d]pyridazin-7-yloxy)methyl)-N-methylpicolinamide;4-[[[4-[(4-Chlorophenyl)amino]furo[2,3-d]pyridazin-7-yl]oxy]methyl]-N-methyl-2-pyridinecarboxamide Telatinib(BAY57-9352);Telatnib
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|
Properties
Boiling point :713.6±60.0 °C(Predicted)
Density :1.417
storage temp. :Store at -20°C
solubility :insoluble in H2O; insoluble in EtOH; ≥20.5 mg/mL in DMSO
form :solid
pka :14.18±0.46(Predicted)
color :White to light yellow
Density :1.417
storage temp. :Store at -20°C
solubility :insoluble in H2O; insoluble in EtOH; ≥20.5 mg/mL in DMSO
form :solid
pka :14.18±0.46(Predicted)
color :White to light yellow
Safety Information
| Symbol(GHS): |
|
|||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal word: | Warning | |||||||||||||||||||||||||||||||||||
| Hazard statements: |
|
|||||||||||||||||||||||||||||||||||
| Precautionary statements: |
|
Description
Telatinib is a multi-kinase inhibitor that inhibits VEGF receptor 2 (VEGFR2), VEGFR3, PDGFRα, and c-Kit (IC50s = 6, 4, 15, and 1 nM, respectively). It also binds to the transmembrane region of the ABCG2 efflux transporter and enhances intracellular accumulation of [3H]-mitoxantrone in ABCG2-overexpressing cells. Telatinib (15 mg/kg) decreases tumor growth rate and size in an H460/MX20 mouse xenograft model.More related product prices
Afatinib Bosutinib Erlotinib Crenolanib Ibrutinib MG-132 Dasatinib Nintedanib Axitinib Telatinib Canertinib Fruquintinib|HMPL-013 Nilotinib